secwatch.observer — SEC 8-K summary
======================================

Issuer:     T2 Biosystems, Inc. (—)
CIK:        0001492674
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001193125-25-027311
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

T2 Biosystems cuts substantially all staff after Nasdaq delisting; top execs as consultants
--------------------------------------------------------------------------------

- Board approved RIF of substantially all employees; expects $1.0M severance costs in Q1 2025.
- CEO Sperzel, CFO Sprague, GC Gibbs terminated without cause, re-hired as consultants at $276.44-$187.50/hr for 20 hrs/week.
- Nasdaq notified company Feb 10 it will file Form 25 to delist; trading moved to OTC on Feb 12.
- Canceled March 3 special meeting for reverse stock split after delisting determination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492674/000119312525027311/0001193125-25-027311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492674/000119312525027311/d926272d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-027311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer